Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

265 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Short communication. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy.
Fuster D, Huertas JA, Gómez G, Solà R, González García J, Vilaró J, Pedrol E, Force L, Tor J, Sirera G, Videla S, Planas R, Clotet B, Tural C; PEG-TOX Research Group. Fuster D, et al. Among authors: planas r. Antivir Ther. 2005;10(7):841-7. Antivir Ther. 2005. PMID: 16312180 Clinical Trial.
Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy.
Fuster D, Planas R, Muga R, Ballesteros AL, Santos J, Tor J, Sirera G, Guardiola H, Salas A, Cabré E, Ojanguren I, Barluenga E, Rey-Joly C, Clotet B, Tural C. Fuster D, et al. Among authors: planas r. AIDS Res Hum Retroviruses. 2004 Dec;20(12):1293-7. doi: 10.1089/aid.2004.20.1293. AIDS Res Hum Retroviruses. 2004. PMID: 15650421
Mitochondrial effects of a 24-week course of pegylated-interferon plus ribavirin in asymptomatic HCV/HIV co-infected patients on long-term treatment with didanosine, stavudine or both.
Ballesteros AL, Miró O, López S, Fuster D, Videla S, Martínez E, Garrabou G, Salas A, Côté H, Tor J, Rey-Joly C, Planas R, Clotet B, Tural C. Ballesteros AL, et al. Among authors: planas r. Antivir Ther. 2004 Dec;9(6):969-77. Antivir Ther. 2004. PMID: 15651755 Clinical Trial.
Poor response to hepatitis C virus (HCV) therapy in HIV- and HCV-coinfected patients is not due to lower adherence to treatment.
Solà R, Galeras JA, Montoliu S, Tural C, Force L, Torra S, Montull S, Castro ER, Coll S, Fuster D, Barrufet P, Sirera G, Giménez MD, Clotet B, Planas R. Solà R, et al. Among authors: planas r. AIDS Res Hum Retroviruses. 2006 May;22(5):393-400. doi: 10.1089/aid.2006.22.393. AIDS Res Hum Retroviruses. 2006. PMID: 16706615 Clinical Trial.
Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study.
Tural C, Solà R, Rubio R, Santín M, Planas R, Quereda C, Berenguer J, Montes-Ramírez M, Clotet B; CORAL-1 study group. Tural C, et al. Among authors: planas r. J Viral Hepat. 2007 Oct;14(10):704-13. doi: 10.1111/j.1365-2893.2007.00860.x. J Viral Hepat. 2007. PMID: 17875005 Clinical Trial.
265 results